{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:32:17Z","timestamp":1768879937886,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40261-025-01504-0","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T11:35:16Z","timestamp":1764070516000},"page":"37-48","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of Non-severe COVID-19 with Molnupiravir: A Systematic Review with Meta-analysis and Trial Sequential Analysis of the Evidence from Randomized Controlled Trials"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6437-930X","authenticated-orcid":false,"given":"George N.","family":"Okoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Askin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasheda","family":"Rabbani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"1504_CR1","unstructured":"Centers for Disease Control and Prevention. If You Get Sick with COVID-19, Antiviral Treatments Can Protect You Against Severe Illness: National Center for Immunization and Respiratory Diseases; 2023. https:\/\/www.cdc.gov\/respiratory-viruses\/whats-new\/antiviral-treatments.html. Accessed 13 Feb 2024."},{"key":"1504_CR2","unstructured":"United States Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for Lagevrio\u2122 (molnupiravir) capsules Maryland, USA: United States Food and Drug Administration; 2023. https:\/\/www.fda.gov\/media\/155054\/download. Accessed 26 July 2023."},{"issue":"7","key":"1504_CR3","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1002\/jmv.27730","volume":"94","author":"S Masyeni","year":"2022","unstructured":"Masyeni S, Iqhrammullah M, Frediansyah A, et al. Molnupiravir: a lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-a narrative review. J Med Virol. 2022;94(7):3006\u201316.","journal-title":"J Med Virol"},{"issue":"5","key":"1504_CR4","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.molcel.2020.07.027","volume":"79","author":"F Robson","year":"2020","unstructured":"Robson F, Khan KS, Le TK, et al. Coronavirus RNA proofreading: molecular basis and therapeutic targeting. Mol Cell. 2020;79(5):710\u201327.","journal-title":"Mol Cell"},{"issue":"541","key":"1504_CR5","doi-asserted-by":"publisher","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","volume":"12","author":"TP Sheahan","year":"2020","unstructured":"Sheahan TP, Sims AC, Zhou ST, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12(541):eabb5883.","journal-title":"Sci Transl Med."},{"issue":"9","key":"1504_CR6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","volume":"28","author":"F Kabinger","year":"2021","unstructured":"Kabinger F, Stiller C, Schmitzoval J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740.","journal-title":"Nat Struct Mol Biol"},{"issue":"4","key":"1504_CR7","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s11845-022-03139-y","volume":"192","author":"KR Mali","year":"2023","unstructured":"Mali KR, Eerike M, Raj GM, et al. Efficacy and safety of molnupiravir in COVID-19 patients: a systematic review. Ir J Med Sci (1971). 2023;192(4):1665\u201378.","journal-title":"Ir J Med Sci (1971)"},{"issue":"6","key":"1504_CR8","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3390\/idr15060061","volume":"15","author":"I Karniadakis","year":"2023","unstructured":"Karniadakis I, Mazonakis N, Tsioutis C, et al. Oral molnupiravir and nirmatrelvir\/ritonavir for the treatment of COVID-19: a literature review with a focus on real-world evidence. Infect Dis Rep. 2023;15(6):662\u201378.","journal-title":"Infect Dis Rep"},{"issue":"11","key":"1504_CR9","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1093\/jac\/dkad275","volume":"78","author":"CS Kow","year":"2023","unstructured":"Kow CS, Ramachandram DS, Hasan SS. Is molnupiravir a wise investment? Reassessing COVID-19 treatment strategies. J Antimicrob Chemoth. 2023;78(11):2779\u201380.","journal-title":"J Antimicrob Chemoth"},{"key":"1504_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107096","volume":"18","author":"B Zheng","year":"2024","unstructured":"Zheng B, Zhao Q, Yang W, et al. Small-molecule antivirals treatment for COVID-19: a systematic review and network meta-analysis. Int J Antimicrob Agents. 2024;18:107096.","journal-title":"Int J Antimicrob Agents"},{"key":"1504_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105768","volume":"221","author":"M Zur","year":"2024","unstructured":"Zur M, Peselev T, Yanko S, et al. Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: systematic review and network meta-analysis. Antivir Res. 2024;221:105768.","journal-title":"Antivir Res"},{"issue":"12","key":"1504_CR12","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1093\/jac\/dkad336","volume":"78","author":"M Sun","year":"2023","unstructured":"Sun M, Lai H, Zhang Z, et al. Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients-authors\u2019 response. J Antimicrob Chemother. 2023;78(12):3009\u201312.","journal-title":"J Antimicrob Chemother"},{"key":"1504_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28889","author":"B Amani","year":"2023","unstructured":"Amani B, Akbarzadeh A, Amani B, et al. Comparative efficacy and safety of nirmatrelvir\/ritonavir and molnupiravir for COVID-19: a systematic review and meta-analysis. J Med Virol. 2023;95(6):e28889.","journal-title":"J Med Virol"},{"key":"1504_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106870","author":"FY Tian","year":"2023","unstructured":"Tian FY, Feng QY, Chen ZY. Efficacy and safety of molnupiravir treatment for COVID-19: a systematic review and meta-analysis of randomized controlled trials. Int J Antimicrob Agents. 2023;62(2):106870.","journal-title":"Int J Antimicrob Agents"},{"key":"1504_CR15","doi-asserted-by":"crossref","unstructured":"Benaicha K, Khenhrani RR, Veer M, et al. Efficacy of molnupiravir for the treatment of mild or moderate COVID-19 in adults: a meta-analysis. Cureus J Med Sci. 2023;15(5):e38586.","DOI":"10.7759\/cureus.38586"},{"issue":"8","key":"1504_CR16","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.cmi.2023.04.014","volume":"29","author":"Y Gao","year":"2023","unstructured":"Gao Y, Liu M, Li ZF, et al. Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials. Clin Microbiol Infect. 2023;29(8):979\u201399.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"1504_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-064498","volume":"13","author":"JJ Petersen","year":"2023","unstructured":"Petersen JJ, Jorgensen CK, Faltermeier P, et al. Drug interventions for prevention of COVID-19 progression to severe disease in outpatients: a systematic review with meta-analyses and trial sequential analyses (The LIVING Project). BMJ Open. 2023;13(6):e064498.","journal-title":"BMJ Open"},{"issue":"2","key":"1504_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/14787210.2021.1961579","volume":"20","author":"GN Okoli","year":"2022","unstructured":"Okoli GN, Rabbani R, Al-Juboori A, et al. Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis. Expert Rev Anti Infe. 2022;20(2):267\u201378.","journal-title":"Expert Rev Anti Infe"},{"issue":"9","key":"1504_CR19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/23744235.2021.1923799","volume":"53","author":"GN Okoli","year":"2021","unstructured":"Okoli GN, Rabbani R, Copstein L, et al. Remdesivir for coronavirus disease 2019 (COVID-19): a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Infect Dis Nor. 2021;53(9):691\u20139.","journal-title":"Infect Dis Nor"},{"issue":"4","key":"1504_CR20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1370\/afm.3120","volume":"22","author":"GN Okoli","year":"2024","unstructured":"Okoli GN, Askin N, Rabbani R. Nirmatrelvir\/ritonavir regimen for mild\/moderately severe COVID-19: a rapid review with meta-analysis and trial sequential analysis. Ann Fam Med. 2024;22(4):336\u201346.","journal-title":"Ann Fam Med"},{"issue":"8","key":"1504_CR21","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1080\/03007995.2024.2366443","volume":"40","author":"GN Okoli","year":"2024","unstructured":"Okoli GN, Reddy VK, Lam OL, et al. Update on efficacy of the approved remdesivir regimen for treatment of COVID-19: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Curr Med Res Opin. 2024;40(8):1277\u201387.","journal-title":"Curr Med Res Opin"},{"key":"1504_CR22","volume-title":"Methodological expectations of cochrane intervention reviews (MECIR)","author":"J Higgins","year":"2016","unstructured":"Higgins J, Lasserson T, Chandler J, et al. Methodological expectations of cochrane intervention reviews (MECIR). London: Cochrane; 2016."},{"key":"1504_CR23","unstructured":"World Health Organization. WHO handbook for guideline development. Geneva, Switzerland: World Health Organization; 2014. https:\/\/www.who.int\/publications\/i\/item\/9789241548960. Accessed 10 Nov 2024."},{"issue":"372","key":"1504_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29(372):n71.","journal-title":"BMJ"},{"key":"1504_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel DM, et al. PRESS Peer review of electronic search strategies: 2015 Guideline Statement. J Clin Epidemiol. 2016;75:40\u20136.","journal-title":"J Clin Epidemiol"},{"key":"1504_CR26","unstructured":"The Cochrane Collaboration. Cochrane COVID-19 Study Register London, United Kingdom: The Cochrane Collaboration. https:\/\/covid-19.cochrane.org\/. Accessed 7 Oct 2020."},{"issue":"7798","key":"1504_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/d41586-020-00694-1","volume":"579","author":"Q Chen","year":"2020","unstructured":"Chen Q, Allot A, Lu Z. Keep up with the latest coronavirus research. Nature. 2020;579(7798):193.","journal-title":"Nature"},{"key":"1504_CR28","unstructured":"World Health Organization. COVID-19: Global literature on coronavirus disease Geneva, Switzerland: The World Health Organization. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/global-research-on-novel-coronavirus-2019-ncov. Accessed 7 Oct 2020."},{"issue":"366","key":"1504_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;28(366):l4898.","journal-title":"BMJ"},{"issue":"11","key":"1504_CR30","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"issue":"7304","key":"1504_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","volume":"323","author":"JA Sterne","year":"2001","unstructured":"Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323(7304):101\u20135.","journal-title":"BMJ"},{"issue":"7454","key":"1504_CR32","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Atkins","year":"2004","unstructured":"Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.","journal-title":"BMJ"},{"issue":"1","key":"1504_CR33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","volume":"61","author":"J Wetterslev","year":"2008","unstructured":"Wetterslev J, Thorlund K, Brok J, et al. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61(1):64\u201375.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"1504_CR34","doi-asserted-by":"publisher","first-page":"EVIDoa2100044","DOI":"10.1056\/EVIDoa2100044","volume":"1","author":"JR Arribas","year":"2022","unstructured":"Arribas JR, Bhagani S, Lobo SM, et al. Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19. NEJM Evid. 2022;1(2):EVIDoa2100044.","journal-title":"NEJM Evid"},{"issue":"10373","key":"1504_CR35","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","volume":"401","author":"CC Butler","year":"2023","unstructured":"Butler CC, Hobbs FDR, Gbinigie OA, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401(10373):281\u201393.","journal-title":"Lancet"},{"key":"1504_CR36","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100043","author":"Y Caraco","year":"2022","unstructured":"Caraco Y, Crofoot GE, Moncada PA, et al. Phase 2\/3 trial of molnupiravir for treatment of Covid-19 in nonhospitalized adults. NEJM Evid. 2022;1(2):EVIDoa2100043.","journal-title":"NEJM Evid"},{"issue":"628","key":"1504_CR37","doi-asserted-by":"publisher","first-page":"eabl7430","DOI":"10.1126\/scitranslmed.abl7430","volume":"14","author":"WA Fischer","year":"2022","unstructured":"Fischer WA, Eron JJ, Holman W, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022;14(628):eabl7430.","journal-title":"Sci Transl Med."},{"issue":"6","key":"1504_CR38","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"A Jayk Bernal","year":"2022","unstructured":"Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509\u201320.","journal-title":"N Engl J Med"},{"issue":"8","key":"1504_CR39","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.7326\/M22-0729","volume":"175","author":"MG Johnson","year":"2022","unstructured":"Johnson MG, Puenpatom A, Moncada PA, et al. Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19. Ann Intern Med. 2022;175(8):1126\u201334.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1504_CR40","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1473-3099(22)00644-2","volume":"23","author":"SH Khoo","year":"2023","unstructured":"Khoo SH, FitzGerald R, Saunders G, et al. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Infect Dis. 2023;23(2):183\u201395.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"1504_CR41","first-page":"e31508","volume":"14","author":"S Sinha","year":"2022","unstructured":"Sinha S, Suram VK, et al. Efficacy and safety of molnupiravir in mild COVID-19 patients in India. Cureus. 2022;14(11):e31508.","journal-title":"Cureus."},{"key":"1504_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.939573","volume":"13","author":"R Zou","year":"2022","unstructured":"Zou R, Peng L, Shu D, et al. Antiviral efficacy and safety of molnupiravir against omicron variant infection: a randomized controlled clinical trial. Front Pharmacol. 2022;13:939573.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1504_CR43","first-page":"147","volume":"21","author":"O Puhach","year":"2023","unstructured":"Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics. Nat Rev Microbiol. 2023;21(3):147\u201361.","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"1504_CR44","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3201\/eid2805.220197","volume":"28","author":"K Takahashi","year":"2022","unstructured":"Takahashi K, Ishikane M, Ujiie M, et al. Duration of infectious virus shedding by SARS-CoV-2 omicron variant-infected vaccinees. Emerg Infect Dis. 2022;28(5):998\u20131001.","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"1504_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1056\/NEJMc2202092","volume":"387","author":"J Boucau","year":"2022","unstructured":"Boucau J, Marino C, Regan J, et al. Duration of shedding of culturable virus in SARS-CoV-2 omicron (BA.1) infection. New Engl J Med. 2022;387(3):275\u20137.","journal-title":"New Engl J Med."},{"key":"1504_CR46","first-page":"13","volume":"7","author":"HF Zhu","year":"2022","unstructured":"Zhu HF, Li MT, Tian C, et al. Efficacy and safety of chinese herbal medicine for treating mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials and observational studies. Front Pharmacol. 2022;7:13.","journal-title":"Front Pharmacol"},{"key":"1504_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28621","author":"PY Huang","year":"2023","unstructured":"Huang PY, Liu TH, Wu JY, et al. Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: a systematic review and meta-analysis of randomized control trials. J Med Virol. 2023;95(3):e28621.","journal-title":"J Med Virol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01504-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01504-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01504-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:37:23Z","timestamp":1768833443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01504-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1504"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01504-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No financial support was received for the conduct of this study, or for the preparation or publication of this manuscript. All authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All data and materials associated with this study are reported in the manuscript and Online Resources.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Conceptualisation (G.N.O.); methods (G.N.O. & R.R.); data procurement (G.N.O. & N.A.); analysis (G.N.O. & R.R.); study validation (G.N.O. & R.R.); original draft of the manuscript (G.N.O.); revisions to the manuscript (G.N.O., N.A. & R.R.); approval for submission (G.N.O., N.A. & R.R.); principal investigator (G.N.O.). All authors read and agreed the final version of the manuscript and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contributions"}}]}}